Seminars in Oncology
Volume 33, Supplement 10 , Pages S26-S34, October 2006

Bevacizumab in the Treatment of Metastatic Colorectal Cancer: Safety Profile and Management of Adverse Events

  • Herbert Hurwitz

      Affiliations

    • Dr Hurwitz has received research support from Genentech, Roche, Pfizer, AstraZeneca, GlaxoSmithKline, Sunesis, Bristol-Myers Squibb, and Sanofi-Aventis. Dr Saini has received research support from GlaxoSmithKline.
    • Corresponding Author InformationAddress reprint requests to Herbert Hurwitz, MD, Box 3052, Room 3802 Red Zone, Duke South Clinics, Duke University Medical Center, Durham, NC 27710, USA.
    • ,
  • Shermini Saini

Duke University Medical Center, Durham, North Carolina.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0093-7754(06)00312-5

doi:10.1053/j.seminoncol.2006.08.001

Seminars in Oncology
Volume 33, Supplement 10 , Pages S26-S34, October 2006

Article Tools